Literature DB >> 9308140

Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study.

W A Zamboni1, H P Wong, L L Stephenson, M A Pfeifer.   

Abstract

The purpose of this study was to prospectively evaluate the effect of hyperbaric oxygen (HBO2) on the healing of diabetic lower extremity wounds. Ten consecutive insulin-dependent diabetic patients with chronic lower extremity wounds were referred for HBO2 treatment. The control group consisted of five patients, two claustrophobic and three rural. The latter refused HBO2 treatments because of logistic reasons. Five patients underwent 30 HBO2 treatments in the problem wound protocol (100% oxygen, 2 atm abs, 2 h/day, 5 days/wk). All patients were evaluated with transcutaneous oxygen measurements and had an initial surgical debridement of the wound. Weekly tracings of the wound surface area were made by a nurse or resident who was blinded to the group assignment. At the end of 7 wk, the mean wound area expressed as a percentage of pretreatment baseline area was compared between groups (analysis of variance, Duncan's post hoc). No significant differences were noted between groups with respect to age, gender, baseline wound area, wound site O2 tension, or presence of osteomyelitis. At the completion of each of the 7-wk treatment periods, a significantly greater reduction in wound surface area was noted in the HBO2 vs. the control group (P < 0.05). HBO2 treatment significantly reduced wound size compared to controls in this small, non-randomized prospective study. These results should serve as a basis for larger multicenter prospective, randomized, double-blind controlled studies to definitively evaluate the effect of HBO2 on the healing of diabetic foot wounds.

Entities:  

Mesh:

Year:  1997        PMID: 9308140

Source DB:  PubMed          Journal:  Undersea Hyperb Med        ISSN: 1066-2936            Impact factor:   0.698


  21 in total

Review 1.  Wound microbiology and associated approaches to wound management.

Authors:  P G Bowler; B I Duerden; D G Armstrong
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 2.  Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing.

Authors:  Omaida C Velazquez
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

Review 3.  Diagnostics and treatment of the diabetic foot.

Authors:  Jan Apelqvist
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

4.  A retrospective study of diabetic foot ulcers treated with hyperbaric oxygen therapy.

Authors:  Alexandra J Bishop; Elizabeth Mudge
Journal:  Int Wound J       Date:  2012-02-28       Impact factor: 3.315

5.  The use of Matriderm and autologous skin grafting in the treatment of diabetic ulcers: a case report.

Authors:  Valerio Cervelli; Lucilla Lucarini; Caterina Cerretani; Diana Spallone; Ludovico Palla; Lorenzo Brinci; Barbara De Angelis
Journal:  Int Wound J       Date:  2010-06-08       Impact factor: 3.315

Review 6.  Hyperbaric oxygen therapy for chronic wounds.

Authors:  Peter Kranke; Michael H Bennett; Marrissa Martyn-St James; Alexander Schnabel; Sebastian E Debus; Stephanie Weibel
Journal:  Cochrane Database Syst Rev       Date:  2015-06-24

Review 7.  Hyperbaric oxygen therapy.

Authors:  Jayesh Shah
Journal:  J Am Col Certif Wound Spec       Date:  2010-04-24

8.  Hyperbaric oxygen therapy for non-healing ulcers in diabetes mellitus: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-09-01

Review 9.  Diabetic foot ulcers treated with hyperbaric oxygen therapy: a review of the literature.

Authors:  Alexandra J Bishop; Elizabeth Mudge
Journal:  Int Wound J       Date:  2012-07-02       Impact factor: 3.315

Review 10.  Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing.

Authors:  Zhao-Jun Liu; Omaida C Velazquez
Journal:  Antioxid Redox Signal       Date:  2008-11       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.